Background
Methods
Clinical Features of AML Patients
CD34+ Cells Mobilization in PB of AML Patients
Selection of CD34+ Cells
In Vitro ChemoSensitivity Assay Of Hematopoietic Precursors
Real Time PCR
Network Analysis
Results
In Vitro ChemoSensitivity Of Hematopoietic Precursors
AM Expression Profile in CD34+ Cells from CR AML Patients
Genes | chemoresistant vs control | chemosensitive vs control | chemoresistant vs chemosensitive | Genes | chemoresistant vs control | chemosensitive vs control | chemoresistant vs chemosensitive |
---|---|---|---|---|---|---|---|
ABL1
| 1.05 (0.85) | -1.04 (1) | -1.11 (1) |
CASP7
| -2.08 (0.14) | -2 (0.03) | -1.26 (0.17) |
AKT1
| -1.55 (0.15) | -1.05 (0.87) | -1.79 (0.18) |
CASP8
| -15.74 (0.006) | -19.29 (0.04) | 1.01 (1) |
APAF1
| 1.35 (0.29) | 2.66 (0.08) | -2.38 (0.007) |
CASP9
| -1.95 (0.20) | -1.46 (0.08) | -1.61 (0.09) |
BAD
| 1.35 (0.26) | 1.47 (0.20) | -1.32 (0.46) |
CD27
| -1.49 (0.24) | -2.33 (0.11) | 1.29 (0.99) |
BAG1
| 1.75 (0.34) | 1.55 (0.47) | -1.07 (1) |
CD40
| -3.11 (0.02) | -4.89 (0.01) | 1.3 (0.50) |
BAG3
| -41.26 (0.0004) | -76.11 (0.00009) | 1.53 (1) |
CD40LG
| -16.3 (0.01) | -2.57 (0.04) | -7.67 (0.02) |
BAG4
| -2.34 (0.09) | -2.99 (0.08) | 1.06 (1) |
CD70
| -10.31 (0.002) | -17.03 (0.01) | 1.37 (0.62) |
BAK1
| -1.11 (1) | -1.26 (0.47) | -1.06 (1) |
CFLAR
| -51.86 (0.002) | -22.01 (0.003) | -2.85 (0.03) |
BAX
| 1.43 (0.80) | 1.31 (0.73) | -1.11 (1) |
CIDEA
| -15.74 (0.008) | -19.29 (0.009) | 1.01 (1) |
BCL10
| 3.09 (0.007) | 3.01 (0.007) | 1.01 (1) |
CIDEB
| 1.26 (0.37) | 2.55 (0.03) | -2.45 (0.001) |
BCL2
| 2.15 (0.12) | 1.9 (0.23) | -1.35 (0.30) |
CRADD
| -1.24 (0.18) | -1.77 (0.07) | 1.18 (0.52) |
BCL2A1
| -5.19 (0.01) | -2.81 (0.02) | -2.23 (0.004) |
DAPK1
| -15.74 (0.0006) | -19.29 (0.0002) | 1.01 (1) |
BCL2L1
| -3.5 (0.007) | 1.06 (0.44) | -4.47 (0.005) |
DFFA
| 3.11 (0.00008) | 3.01 (0.00009) | 1.01 (1) |
BCL2L10
| -15.74 (0.01) | -19.29 (0.02) | 1.01 (1) |
FADD
| -5.02 (0.004) | -6.41 (0.004) | 1.06 (1) |
BCL2L11
| 1.36 (0.25) | 1.38 (0.26) | -1.22 (0.72) |
FAS
| -7.19 (0.01) | -3.53 (0.04) | -2.46 (0.003) |
BCL2L2
| -1.25 (0.24) | -1.04(1) | -1.44 (0.21) |
FASLG
| -22.58 (0.005) | -4.32 (0.02) | -6.32 (0.01) |
BCLAF1
| 3.12 (0.003) | 3.04(0.002) | 1.01 (1) |
GADD45A
| -2.09 (0.16) | -2.69 (0.22) | 1.06 (1) |
BFAR
| 3.01 (0.0006) | 1.84(0.03) | 1.01 (1) |
HRK
| -3.75 (0.01) | -6.11 (0.01) | 1.35 (0.30) |
BID
| -1.03 (0.93) | 1.16 (0.43) | -1.44 (0.21) |
IGF1R
| -2.29 (0.08) | -3.16 (0.07) | 1.14 (1) |
BIK
| 1.1 (1) | 1.47 (0.34) | -1.61 (0.38) |
LTA
| -7.34 (0.05) | -4.72 (0.01) | -1.88 (0.12) |
BIRC2
| 3.77 (0.006) | -7.26 (0.004) | 22.63 (0.001) |
LTBR
| -1.38 (0.25) | -1.13 (0.47) | -1.47 (0.27) |
BIRC3
| -3.02 (0.001) | -10.13 (0.004) | 2.77 (0.001) |
MCL1
| 1.51 (0.33) | 1.34 (0.46) | -1.07 (0.51) |
BIRC4
| -11.77 (0.0007) | -15.14 (0.0007) | 1.06 (1) |
NAIP
| 1.96 (0.13) | 1.39 (0.34) | 1.16 (1) |
BIRC6
| -1.08 (0.85) | 1.04 (0.73) | -1.37 (0.18) |
NOD1
| -1.31 (0.36) | -1.09 (0.94) | -1.44 (0.75) |
BIRC8
| -17.71 (0.0005) | -21.71 (0.0002) | 1.01 (1) |
NOL3
| -15.74 (0.001) | -10.34 (0.0003) | -1.84 (0.21) |
BNIP1
| -9.17 (0.0008) | -10.41 (0.001) | -1.06 (1) |
PYCARD
| 1.12 (0.48) | 1.79 (0.07) | -1.93 (0.05) |
BNIP2
| -8.15 (0.005) | -7.52 (0.007) | -1.31 (0.24) |
RIPK2
| -1.11 (0.21) | -1.69 (0.48) | 1.26 (0.08) |
BNIP3
| -8.38 (0.02) | -9.71 (0.03) | -1.04 (1) |
TNF
| 2.08 (0.18) | 2.3 (0.31) | -1.34 (0.29) |
BNIP3L
| -3.75 (0.02) | -4.41 (0.01) | -1.03 (1) |
TNFRSF10A
| -6.13 (0.013) | -4.03 (0.01) | -1.84 (0.13) |
BRAF
| -1.09 (0.83) | -1.27 (0.15) | -1.04 (1) |
TNFRSF10B
| -5.72 (0.016) | -4.92 (0.02) | -1.4 (0.43) |
CARD6
| -15.74 (0.001) | -19.29 (0.0008) | 1.01 (1) |
TNFRSF11B
| -15.74 (0.007) | -19.29 (0.007) | 1.01 (1) |
CARD8
| -4.55 (0.01) | -3.76 (0.01) | -1.46 (0.19) |
TNFRSF1A
| 2.42 (0.13) | 1.65 (0.11) | 1.21 (0.76) |
CASP1
| -1.35 (0.45) | 1.06 (0.48) | -1.74 (0.01) |
TNFRSF21
| 1.1 (0.29) | -1.48 (0.83) | 1.35 (0.12) |
CASP10
| -5.12 (0.01) | -6.5 (0.012) | 1.05 (1) |
TNFRSF25
| 1.07 (1) | 3.61 (0.03) | -4.06 (0.03) |
CASP14
| -25.4 (0.03) | -58.89 (0.0004) | 1.92 (0.02) |
TNFRSF9
| -15.74 (0.03) | -18.38 (0.01) | -1.04 (1) |
CASP2
| 1.05 (1) | 1.1 (1) | -1.27 (1) |
TNFSF10
| -1.25 (0.12) | 1.45 (0.08) | -2.2 (0.01) |
CASP3
| 1.07 (1) | -1.13 (0.68) | -1.01 (1) |
TNFSF8
| -9.04 (0.007) | -10.7 (0.008) | -1.02 (1) |
CASP4
| -1.47 (0.08) | -1.57 (0.09) | -1.13 (0.72) |
TP53
| 1.27 (0.20) | 1.2 (0.23) | -1.14 (0.70) |
CASP5
| -12.27 (0.002) | -11.71 (0.002) | -1.27 (0.16) |
TP53BP2
| -15.74 (0.02) | -19.29 (0.003) | 1.01 (1) |
CASP6
| 1.2 (0.34) | 1.2 (0.43) | -1.21 (0.99) |
TP73
| -53.32 (0.006) | -48.5 (0.006) | -1.33 (0.70) |
Gene Symbol | Category | Expression | NOTES |
---|---|---|---|
BAG3 | Anti | Down | Down expression of BAG3 increases apoptosis induced via Bax or Fas by IL-3 deprivation in hematopoietic cells. Furthermore, BAG3 down modulation is recently shown to enhance the apoptotic response to chemotherapy with alkylating agents through regulation of CHK2 and CDC2 proteins in human primary B chronic lymphocytic leukemia cells. |
BCL10 | Pro | Up | This gene contains a CARD domain, and has been shown to induce apoptosis and to activate NF-kappaB. It is interesting that deregulation of this gene leads to pathogenesis of hematopoietic malignancy. We detected it in HSC from our cohort of patients. Its over expression in CR CD34+ cells could be related to their proneness to death induction. |
BCL2L10 | Pro | Down | The protein of this gene act as pro-apoptotic regulators that are involved in a wide variety of cellular activities, interacting with other members of BCL-2 protein family including BCL2, BCL2L1/BCL-X(L), and BAX. |
BCLAF1 | Pro | Up | This gene encodes a transcriptional repressor that interacts with several members of the BCL2 family. Its overexpression induces apoptosis. |
BIRC4 | Anti | Down | It is a protein which inhibits apoptosis through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2. It also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. |
BIRC8 | Anti | Down | BIRC8 is involved in the control of apoptosis by direct inhibition of caspase 9. |
BNIP1 | Anti | Down | BNIP genes area members of the BCL2/adenovirus E1B 19 kd-interacting protein (BNIP) family. They interact with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell death, as well as, E1B 19 kDa-like sequences of BCL2. |
BNIP2 | Anti | Down | |
BNIP3 | Pro/Anti | Down | BNIP3 interacts with the E1B 19 kDa protein which is responsible for the protection of virally-induced cell death, as well as E1B 19 kDa-like sequences of BCL2. The dimeric mitochondrial protein is known to induce apoptosis, even in the presence of BCL2. |
CARD6 | Anti | Down | This protein is a microtubule-associated protein that has been shown to interact with receptor-interacting protein kinases and positively modulate signal transduction pathways converging on activation of the inducible transcription factor NF-kB. |
CASP14 | Pro | Down | Caspases encode members of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis by inducing of either TNF or FAS-receptor. |
CASP5 | Pro | Down | |
CD70 | Pro | Down | This cytokine is also reported to play a role in regulating B-cell activation, cytotoxic function of natural killer cells, and immunoglobulin synthesis. Its downexpression could confirm that CD34+ cells from these patients have an expression profile prone to apoptosis and to positively respond to chemotherapy |
CFLAR | Anti | Down | c-FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors, such as Fas. Furthermore, overexpression of c-FLIP potently inhibits apoptosis induced by chemotherapy, suggesting that c-FLIP has a role in mediating chemoresistance. |
CIDEA | Pro | Down | Cidea that has been shown to activate apoptosis by disrupting a complex consisting of DFF40/CAD. |
DAPK1 | Pro | Down | This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in patients after chemotherapy. It could be considered a CR marker. |
DFFA | Pro | Up | DFFA is the substrate for caspase-3 and triggers DNA fragmentation during apoptosis. |
NOL3 | Anti | Down | NOL3, an apoptosis suppressor limited to terminally differentiated cells, is induced in human breast cancer and confers chemo-and radiation-resistance. |
TNFRSF11B | Anti | Down | Downexpression of this gene in our model could be considered a CR marker: this gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in patients after chemotherapy |
TNFRSF9 | Anti | Down | This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation. |
TNFSF8 | Anti | Down | This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in patients after chemotherapy. It could be considered a CR marker. |
TP53BP2 | Pro | Down | This protein is localized to the perinuclear region of the cytoplasm, and regulates apoptosis and cell growth through interactions with other regulatory molecules including members of the p53 family. |
TP73 | Pro | Down | This gene commonly results over expressed in hematopoietic malignancies, but it is down regulated in patients after chemotherapy. It could be considered a CR marker. |
Gene Symbol | Category | Expression | NOTES |
---|---|---|---|
APAF1 | pro | Down | It is a component of apoptosome. The apoptosome has a role in chemioresistance in pancreatic cancer. |
BCL2A1 | anti | Down | This gene is able to reduce the release of pro-apoptotic cytochrome c from mitochondria and block caspase activation. This gene is a direct transcription target of NF-kappa B and it acts in response to cytokine TNF and IL-1. |
BCL2L1 | pro/anti | Down | It acts as anti- or pro-apoptotic regulators. This gene is located on mitochondrial membrane and control VDAC opening, regulating the release of cytochrome C by mitochondria. |
BIRC2 | anti | Up | This gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2. |
BIRC3 | anti | Up | This gene is a member of a family of proteins that inhibits apoptosis by binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2. In cells resistant to alkylating agent, it blocks through regulation of CHK2 and CDC2 proteins. |
CD40LG | pro | Down | It regulates B cell function by engaging CD40 on the B cell surface. |
CIDEB | pro | Down | CIDEB triggers DNA fragmentation and nuclear condensation. Its expression could be associated to resistance to apoptosis. |
FAS | pro | Down | FAS/FASL ratio, after receiving chemotherapy, indicates chemosensitivity in several tumoral models. In addition, the decreasing ratio during chemotherapy treatment, despite the initial values, is related to acquired chemoresistance. |
FASLG | pro | Down | |
TNFRSF25 | pro | Down | This receptor has been shown to stimulate NF-kappa B activity and regulate cell apoptosis. The signal transduction of this receptor is mediated by various death domains contained by adaptor proteins. |
TNFSF10 | pro | Down | This protein preferentially induces apoptosis in transformed and tumoral cells and it is expressed at a significant level in the most of normal tissues. Its down regulation could impair the apoptosis induction. |